LV13154B - S-omeprazole (esomeprazole) inclusion complex with cyclodextrins - Google Patents

S-omeprazole (esomeprazole) inclusion complex with cyclodextrins Download PDF

Info

Publication number
LV13154B
LV13154B LVP-04-01A LV040001A LV13154B LV 13154 B LV13154 B LV 13154B LV 040001 A LV040001 A LV 040001A LV 13154 B LV13154 B LV 13154B
Authority
LV
Latvia
Prior art keywords
omeprazole
cyclodextrin
inclusion complex
complex
solution
Prior art date
Application number
LVP-04-01A
Other languages
English (en)
Latvian (lv)
Inventor
Yusuf Khwaja Hamied
Dharmaraj Ramachandra Rao
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of LV13154B publication Critical patent/LV13154B/en

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/724Cyclodextrins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
LVP-04-01A 2001-06-06 2004-01-06 S-omeprazole (esomeprazole) inclusion complex with cyclodextrins LV13154B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0113792A GB2376231A (en) 2001-06-06 2001-06-06 Benzimidazole-cyclodextrin inclusion complex

Publications (1)

Publication Number Publication Date
LV13154B true LV13154B (en) 2004-07-20

Family

ID=9916040

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-04-01A LV13154B (en) 2001-06-06 2004-01-06 S-omeprazole (esomeprazole) inclusion complex with cyclodextrins

Country Status (18)

Country Link
US (1) US20040147481A1 (pt)
EP (1) EP1401442B1 (pt)
JP (1) JP2004536810A (pt)
AT (1) ATE282412T1 (pt)
AU (1) AU2002344386B2 (pt)
CA (1) CA2449769C (pt)
DE (1) DE60201995T2 (pt)
ES (1) ES2232780T3 (pt)
GB (1) GB2376231A (pt)
HK (1) HK1064602A1 (pt)
LT (1) LT5182B (pt)
LV (1) LV13154B (pt)
NZ (1) NZ529956A (pt)
PL (1) PL366940A1 (pt)
PT (1) PT1401442E (pt)
RU (1) RU2313343C2 (pt)
WO (1) WO2002098423A1 (pt)
ZA (1) ZA200309841B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1707217A1 (en) 2004-12-17 2006-10-04 Wacker Chemie AG Process for preparing an alpha lipoic acid/cyclodextrin complex and product prepared
US20060229277A1 (en) * 2005-04-08 2006-10-12 Orbus Pharma, Inc. Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor
ES2325336T3 (es) 2005-12-28 2009-09-01 Union Quimico-Farmaceutica, S.A. Procedimiento para la preparacion del enantiomero (s) de omeprazol.
KR20070069567A (ko) * 2005-12-28 2007-07-03 에스케이케미칼주식회사 저장안정성이 우수한 s-오메프라졸 함유 포접 복합체 및이의 제조방법
US7947840B2 (en) 2007-09-25 2011-05-24 Hetero Drugs Limited Process for preparation of enantiomerically pure esomeprazole
WO2010097583A1 (en) * 2009-02-24 2010-09-02 Cipla Limited Esomeprazole potassium polymorph and its preparation
CN104277030B (zh) * 2013-07-03 2016-04-20 湖南理工学院 一种反应萃取分离泮托拉唑对映体的方法
CN103768028A (zh) * 2014-01-15 2014-05-07 山东新时代药业有限公司 一种注射用埃索美拉唑钠无菌冻干粉末及其制备工艺

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3427787A1 (de) * 1984-07-27 1986-01-30 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Wirkstoffkomplexe von 5-methoxy-2((4-methoxy-3,5-dimethyl-2-pyridyl) methylsulfinyl)-1h-benzimidazol mit cyclodextrinen, deren herstellung und arzneimittel
TW224049B (pt) * 1991-12-31 1994-05-21 Sunkyong Ind Ltd
US5877192A (en) * 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
SE504459C2 (sv) * 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
JPH0948730A (ja) * 1995-06-02 1997-02-18 Takeda Chem Ind Ltd 水溶性の改善されたベンズイミダゾール系抗潰瘍剤含有安定組成物
WO1996038175A1 (en) * 1995-06-02 1996-12-05 Takeda Chemical Industries, Ltd. Stabilized composition comprising an antiulcerative benzimidazole
SE510666C2 (sv) 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
BR9808581A (pt) * 1997-03-13 2000-05-30 Hexal Ag Estabilização de benzimidazóis sensìveis a ácido com combinações de aminoácido/ciclodextrina
PT1018340E (pt) * 1999-01-06 2003-12-31 Tecnimede Sociedade Tecnico Medicinal Sa Complexos de inclusao de sais de aminoacidos de derivados do benzimidazol com ciclodextrinas, sua preparacao e formulacoes farmaceuticas que os contem
US6262085B1 (en) * 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
AU777667B2 (en) * 1999-08-26 2004-10-28 Aaipharma Incorporated Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
SE9903831D0 (sv) * 1999-10-22 1999-10-22 Astra Ab Formulation of substituted benzimidazoles

Also Published As

Publication number Publication date
HK1064602A1 (en) 2005-02-04
PT1401442E (pt) 2005-02-28
ES2232780T3 (es) 2005-06-01
ZA200309841B (en) 2005-03-14
CA2449769A1 (en) 2002-12-12
EP1401442A1 (en) 2004-03-31
DE60201995T2 (de) 2005-11-24
ATE282412T1 (de) 2004-12-15
LT5182B (lt) 2004-12-27
PL366940A1 (en) 2005-02-07
RU2003137221A (ru) 2005-06-10
AU2002344386B2 (en) 2006-11-30
LT2003100A (en) 2004-09-27
DE60201995D1 (de) 2004-12-23
GB0113792D0 (en) 2001-07-25
RU2313343C2 (ru) 2007-12-27
WO2002098423A1 (en) 2002-12-12
GB2376231A (en) 2002-12-11
US20040147481A1 (en) 2004-07-29
CA2449769C (en) 2010-12-14
NZ529956A (en) 2005-07-29
EP1401442B1 (en) 2004-11-17
JP2004536810A (ja) 2004-12-09

Similar Documents

Publication Publication Date Title
DE69720774T2 (de) S-omeprazol in festform
DE60020967T2 (de) Kristalle von lansoprazole
US6410569B1 (en) Salt form of pantoprazole
WO2002012225A1 (fr) Sels de composé à base de benzimidazole et leurs applications
DE69911159T2 (de) Cyclodextrin Einschlusskomplexe mit Aminosäuresalzen von Benzimidazolderivaten, deren Herstellung, sowie diese enthaltende pharmazeutische Zusammensetzungen
EP1401442B1 (en) S-omeprazole (esomeprazole) inclusion complex with cyclodextrins
KR100619200B1 (ko) 개선된 화학적 제조 방법 및 제약 제형
AU2002344386A1 (en) S-omeprazole (esomeprazole) inclusion complex with cyclodextrins
DE602004011946T2 (de) Alkalisalze von protonenpumpen-hemmern
CH698658B1 (de) Orale pharmazeutische Formulierung mit schneller Freisetzung für Pyridylmethylsulfinyl-Benzimidazole.
JP2014169302A (ja) (s)−オメプラゾールのマグネシウム塩の固形形態とその製造方法
JP3283252B2 (ja) ベンズイミダゾール化合物の結晶
WO2005070426A1 (en) Freeze-dried (-)-pantoprazole preparation and (-)-pantoprazole injection
JP2004536810A5 (pt)
US20090030044A1 (en) Crystal of Salt of Benzimidazole Compound
US20070212408A1 (en) Stable Pharmaceutical Composition Containing Benzimidazole Derivatives and Method of Manufacturing the Same
DE10234617B4 (de) Neues Salz von (S)-Pantoprazol
US20050171057A1 (en) Pantoprazole cyclodextrin inclusion complexes
JP2001072675A (ja) ベンズイミダゾール化合物の結晶